ClearPoint Neuro, Inc.
CLPT scores 18.8 on the Conservative profile, blending a fundamental score (80% weight, emphasizing quality and stability (84% of fundamental weight)) with a machine-learning signal (20% weight) trained on 82 features across 30 years of data.
Minor adjustments (-2.0 points) applied. CLPT's rank of #1300 primarily reflects its factor profile relative to the conservative weight vector.
These features are direct inputs to the machine learning model. The model was trained on these signals alongside 100 features (including 12 momentum/technical indicators) to produce the ML percentile score.
| Stock | Score | P/E | Rev Growth | Margin | Mkt Cap |
|---|---|---|---|---|---|
| CLPT | 18.8 | N/A | 31.0% | -67.4% | $421M |
| INCY | 89.9 | 15.8 | 21.2% | 25.0% | $19.6B |
| GMAB | 86.1 | 13.1 | 22.8% | 36.4% | $17.9B |
| CPRX | 83.7 | 13.7 | 23.5% | 37.6% | $3.0B |
| ASND | 78.3 | 16.6 | 98.0% | -31.7% | $13.8B |
| EXEL | 78.3 | 15.1 | 7.0% | 33.7% | $11.9B |
| VRTX | 78.2 | 32.1 | 8.9% | 32.9% | $121.8B |
| NBIX | 75.1 | 26.5 | 21.4% | 16.7% | $13.1B |
| RPRX | 75.0 | 25.1 | 5.1% | 32.4% | $19.3B |
| HOLX | 74.8 | 31.1 | 1.7% | 13.8% | $16.8B |
| AMGN | 74.2 | 26.0 | 10.0% | 21.0% | $204.8B |
| ARGX | 73.7 | 35.1 | 78.6% | 38.0% | $47.4B |
| REGN | 73.0 | 19.4 | 1.0% | 31.4% | $80.2B |
| ALKS | 72.9 | 16.5 | -6.4% | 23.9% | $5.0B |
| ISRG | 72.7 | 61.7 | 20.5% | 28.4% | $180.9B |
| KRYS | 71.5 | 41.4 | 473.0% | 30.7% | $7.9B |
| Sector Average | 36.6 | 41.9 | 161.5% | -3292.7% | โ |
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and ClearPoint Neuro Navigation System, an MRI suite. It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
Stock is building a base after a decline. The 200-day moving average is flattening. Watch for a breakout above the 200-day SMA on increased volume.
| Metric | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| Revenue | $9M | $9M | $8M | $8M |
| Gross Profit | $6M | $6M | $5M | $5M |
| Operating Income | $-5M | $-6M | $-6M | $-6M |
| Net Income | $-6M | $-6M | $-6M | $-5M |
| EPS (Diluted) | $-0.21 | $-0.21 | $-0.22 | $-0.20 |
| Gross Margin | 63.2% | 60.3% | 60.5% | 61.3% |
| Operating Margin | -59.5% | -61.6% | -72.6% | -72.1% |
| Net Margin | -66.5% | -63.3% | -71.0% | -69.3% |
| Year | Low | High | Range | Status |
|---|---|---|---|---|
| 2021 | $10.65 | $25.55 | 82.3% | Wide |
| 2022 | $7.00 | $16.96 | 83.1% | Wide |
| 2023 | $4.05 | $11.00 | 92.4% | Wide |
| 2024 | $5.11 | $17.47 | 109.5% | Wide |
| 2025 | $9.76 | $30.10 | 102.1% | Wide |
Growth estimates have been dampened based on technical and fundamental signals. This is a post-hoc adjustment to prevent overly optimistic projections for stocks showing declining momentum or deteriorating fundamentals.
Scores are generated by a multi-stage ML pipeline combining fundamental analysis, ensemble predictions, and structural risk signals. All data is for research purposes only and does not constitute financial advice. Past performance does not guarantee future results.